Collaborations Pharmaceuticals, Inc. leverages advanced machine learning and artificial intelligence (AI) technologies to enhance drug discovery and toxicology assessments. Their innovative software tools are designed to predict molecular properties, visualize molecular data, and assist in the design of new therapeutic candidates, particularly for rare and neglected diseases. The company focuses on developing clinical candidates by utilizing AI to identify and translate preclinical assets into clinical-stage products. Their capabilities extend to various applications, including predicting toxicity and aiding in regulatory filings, making their technologies valuable for pharmaceutical and consumer product companies alike.

The company has made significant strides in applying machine learning to a diverse range of infectious diseases, including Ebola, HIV, and enteroviruses. Collaborations Pharmaceuticals has developed predictive models that identify molecules with potential in vivo activity, which has led to NIH funding for their drug candidates. Their research includes the discovery of novel compounds with antiviral properties and the development of machine learning models that can rapidly assess the efficacy of these compounds. This approach not only enhances the efficiency of drug development but also raises awareness of the dual-use potential of AI technologies in both therapeutic and regulatory contexts.

United States

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services.

To date we have won with collaborators $23.5M in grants since 2016.

1730 Varsity Drive, Suite 360, Raleigh, NC 27606-5228, US

Collaborations Pharmaceuticals, Inc.

North Carolina

Antiviral Therapies

Collaborations Pharmaceuticals, Inc.

Company Details